ASCO 2017: Serum androgens and survival in metastatic castration resistant prostate cancer patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance)
Chicago, IL (UroToday.com) Higher baseline androgens have been previously shown to be associated with an improved overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with the androgen synthesis inhibitors, ketoconazole or abiraterone. This analysis was performed to determine whether baseline serum androgen levels Testosterone (Testo), Androstenedione (Andro) and DHEA are associated with OS in mCRPC patients treated with docetaxel-based chemotherapy.
ASCO 2017: History of PSA Screening on Prostate Cancer Aggressiveness
Chicago, IL (UroToday.com) In 2012, PSA screening for prostate cancer (PCa) detection was given a “Grade D” recommendation for all men by the US preventative service task force (USPSTF). Recent U.S. studies report declines in PSA screening with concomitant increases in advanced PCa at diagnosis. Dr. Gerald presented a study examining the association between PSA screening history and PCa aggressiveness in a racially diverse, military cohort with equal health care access.
ASCO 2017: P53 status in primary tumor predicts efficacy of first-line abiraterone and enzalutamide in castration-resistant prostate cancer patients
Chicago, IL (UroToday.com) In this study, the authors tested whether tissue-based analysis of p53 and PTEN genomic status, measured predominantly in primary tumor samples, were predictive for sensitivity to abiraterone and enzalutamide in castration resistant prostate cancer (CRPC).
ASCO 2017: A 17-gene panel for prediction of adverse surgical pathology in the setting of MRI-guided prostate biopsy
Chicago, IL (UroToday.com) A 17-gene panel (Oncotype Dx Genomic Prostate Score, GPS) has been validated in the past as an independent predictor of adverse pathology (AP, defined as pathological GS 4+3 or higher and/or pT3+) in men treated with radical prostatectomy (RP) for prostate cancer (PCa). Multiparametric Magnetic Resonance Imaging (mpMRI) may help guide prostate biopsies. Dr. Amirali Salmasi presented a study attempting to explore synergies between GPS and mpMRI to aid in PCa management decisions.
ASCO 2017: Association of loss of tumor suppressor ZFP36 with lethal prostate cancer
Chicago, IL (UroToday.com) Inflammation has been linked to prostate cancer (PCa) progression which may be mediated by the transcription factor nuclear factor kappa B (NFκB). Using a bioinformatic screen focused on NFκB pathway activation in lethal PCa, the authors identified the tumor suppressor ZFP36 as a key node of the NFκB network. Furthermore, the authors had shown in vitro that ZFP36 expression was inversely associated with both NFκB-controlled gene levels, and proliferation and sensitivity to enzalutamide.
ASCO 2017: Association of androgen receptor status in plasma DNA with outcome on enzalutamide or abiraterone or castration resistant prostate cancer
Chicago, IL (UroToday.com) There is an urgent need to identify biomarkers to guide personalized therapy in castrate-resistant prostate cancer (CRPC). Dr. Vincenza Conteduca presented a study aiming to clinically qualify the association of androgen receptor (AR) status in plasma DNA with worse outcome in pre- and post-docetaxel (doc) CRPC.
ASCO 2017: Ten-year overall and prostate cancer specific mortality in high-risk patients after high-dose-rate brachytherapy combined with external beam radiation therapy (HDR-BT/EBRT) compared with EBRT alone
Chicago, IL (UroToday.com) The effect of dose-escalation with high-dose-rate brachytherapy (HDR-BT) boost for high-risk prostate cancer (PCa) is not known. Dr. Trude Wedde presented a retrospective study aiming to compare 10-year PCa-specific mortality (PCSM) and overall mortality (OM) in non-metastatic patients treated with HDR-BT/external beam radiation therapy (EBRT) during the years 2004-2010 to EBRT alone from a historical randomized controlled trial - SPCG-7, 1996-2003).1